Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The aim of the study was to determine whether there is a gender difference in the impact of SERMs on the GH-IGF-I axis.

Why It Was Studied

In men, GH secretion is stimulated by estradiol derived locally from aromatization of testosterone.

Tamoxifen and raloxifene are selective estrogen receptor modulators (SERMs), drugs that block central estrogen action but exert estrogen-like effects in the liver, inhibiting hepatic IGF-I production.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, open-label and crossover.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

The researchers conducted a comparative, randomized, open-label, crossover study of tamoxifen and raloxifene.

What Was Measured

In men, GH secretion is stimulated by estradiol derived locally from aromatization of testosterone.

Topics PubMed links to this paper include Arginine, Human Growth Hormone, Insulin-Like Growth Factor I, Liver, Luteinizing Hormone, Neurosecretion and Pituitary Gland, Anterior.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.